Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBITDA: 2010-2024

Historic EBITDA for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $8.0 million.

  • Ani Pharmaceuticals' EBITDA rose 276.62% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year increase of 515.57%. This contributed to the annual value of $8.0 million for FY2024, which is 85.34% down from last year.
  • Ani Pharmaceuticals' EBITDA amounted to $8.0 million in FY2024, which was down 85.34% from $54.5 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' EBITDA registered a high of $54.5 million during FY2023, and its lowest value of -$34.3 million during FY2021.
  • Moreover, its 3-year median value for EBITDA was $8.0 million (2024), whereas its average is $11.5 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' EBITDA crashed by 205.75% in 2021 and then surged by 295.36% in 2023.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' EBITDA stood at -$11.2 million in 2020, then crashed by 205.75% to -$34.3 million in 2021, then grew by 18.69% to -$27.9 million in 2022, then surged by 295.36% to $54.5 million in 2023, then plummeted by 85.34% to $8.0 million in 2024.